Organon Implanon contraceptive "approvable" again
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Organon receives a second "approvable" letter for its implantable contraceptive Implanon. Although FDA initially deemed the etonogestrel sub-dermal implant approvable in November 2004, the agency has continued to request additional information, Organon said. The original user fee date was in October 2004. The firm plans to meet with FDA to address outstanding issues associated with the review...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.